Trexquant Investment LP Takes $1.42 Million Position in Celldex Therapeutics, Inc. $CLDX

Trexquant Investment LP purchased a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 78,210 shares of the biopharmaceutical company’s stock, valued at approximately $1,420,000. Trexquant Investment LP owned 0.12% of Celldex Therapeutics as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in CLDX. Hsbc Holdings PLC acquired a new position in shares of Celldex Therapeutics in the 4th quarter valued at $233,000. Northern Trust Corp lifted its stake in shares of Celldex Therapeutics by 6.2% in the 4th quarter. Northern Trust Corp now owns 597,605 shares of the biopharmaceutical company’s stock valued at $15,101,000 after purchasing an additional 34,885 shares during the period. Ameriprise Financial Inc. acquired a new position in shares of Celldex Therapeutics in the 4th quarter valued at $251,000. BNP Paribas Financial Markets lifted its stake in shares of Celldex Therapeutics by 122.2% in the 4th quarter. BNP Paribas Financial Markets now owns 62,631 shares of the biopharmaceutical company’s stock valued at $1,583,000 after purchasing an additional 34,450 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Celldex Therapeutics in the 4th quarter valued at $3,905,000.

Analyst Ratings Changes

A number of research firms recently commented on CLDX. Citigroup lowered their price objective on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. The Goldman Sachs Group lowered their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating for the company in a research report on Friday, May 9th. UBS Group lowered their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Wells Fargo & Company lowered their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a research report on Wednesday, August 20th. Finally, Morgan Stanley lowered their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $46.67.

Celldex Therapeutics Trading Up 0.4%

CLDX stock opened at $22.87 on Friday. The stock has a 50-day moving average price of $22.46 and a two-hundred day moving average price of $20.65. The stock has a market cap of $1.52 billion, a PE ratio of -7.60 and a beta of 1.19. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.01. The firm had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. On average, analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.